Skip to content
10-K

Annual Report

Forte Biosciences, Inc. FBRX

0001193125-26-134498

← back to feed
Filed
Mar 31, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 27, 2026 13.89M sh
Capex FY 2025 · Dec 31, 2025 $116K
Capex FY 2025 · Dec 31, 2024 $37K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$50.88M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$30.75M
Cash And Equivalents FY 2025 · Dec 31, 2025 $76.96M
Cash And Equivalents FY 2025 · Dec 31, 2024 $22.24M
Stockholders Equity FY 2025 · Dec 31, 2025 $60.99M
Stockholders Equity FY 2025 · Dec 31, 2024 $52.48M
Stockholders Equity FY 2025 · Dec 31, 2023 $35.31M
Current Liabilities FY 2025 · Dec 31, 2025 $20.75M
Current Liabilities FY 2025 · Dec 31, 2024 $9.08M
Total Liabilities FY 2025 · Dec 31, 2025 $21.79M
Total Liabilities FY 2025 · Dec 31, 2024 $9.08M
Current Assets FY 2025 · Dec 31, 2025 $80.59M
Current Assets FY 2025 · Dec 31, 2024 $61.35M
Total Assets FY 2025 · Dec 31, 2025 $82.78M
Total Assets FY 2025 · Dec 31, 2024 $61.56M
Eps Diluted FY 2025 · Dec 31, 2025 −$4.71
Eps Diluted FY 2025 · Dec 31, 2024 −$12.17
Eps Basic FY 2025 · Dec 31, 2025 −$4.71
Eps Basic FY 2025 · Dec 31, 2024 −$12.17
Sga Expense FY 2025 · Dec 31, 2025 $12.41M
Sga Expense FY 2025 · Dec 31, 2024 $15.41M
Net Income FY 2025 · Dec 31, 2025 −$69.38M
Net Income FY 2025 · Dec 31, 2024 −$35.48M
Operating Income FY 2025 · Dec 31, 2025 −$70.66M
Operating Income FY 2025 · Dec 31, 2024 −$36.6M
Short Term Investments FY 2025 · Dec 31, 2024 $36.12M